Turn Therapeutics announced corporate, financial, and pipeline updates ahead of the 44th Annual J.P. Morgan Healthcare Conference.
The company's Phase 2 trial of GX-03 for moderate-severe atopic dermatitis is on track for interim analysis and topline data in the first half of 2026.
Expansion of intranasal vaccine pipeline to include an influenza candidate and progress on commercial partnerships are key highlights.
Phase 2 Trial Progress
GX-03 trial for atopic dermatitis on track, with interim and topline data expected in 2026.
Corporate Governance Strengthening
Board appointment of Martin Dewhurst brings 30+ years of experience in M&A and strategic guidance.
Vaccine Pipeline Expansion
Influenza vaccine candidate and targeted intranasal exposure enhance growth opportunities.
Commercial Partnership Revenue
Strategic partnership with Medline set to generate revenue in advanced wound care market in 2026.
- Turn Therapeutics is well positioned with an advancing clinical pipeline and strengthened board governance.
- The expansion into vaccine development and commercial partnerships signals growth and revenue generation in 2026.
As Turn Therapeutics gears up for 2026, the company's strategic advancements and clinical progress set the stage for a pivotal year of growth and development in the biotechnology sector.